Doggett Announces Ways & Means Medicare Drug-Pricing Hearing
Published by Inside Health Policy
The House Ways & Means health subcommittee will hold a hearing on promoting competition to lower prescription drug prices in Medicare on March 7, chair Rep. Lloyd Doggett (D-TX) announced Thursday (Feb. 28). The committee is the latest to join the congressional dogpile of hearings on the issue, including a two-day Senate Special Committee on Aging hearing, of which the second session will be held on the same day.
Allowing Medicare to directly negotiate drug prices was a topic of heated discussion during the full Ways & Means drug-pricing hearing on Feb. 12. Overall committee ranking Republican Rep. Kevin Brady (TX) came out staunchly against the proposal. Doggett promoted his price-negotiation bill that includes compulsory licensing as an enforcement tool, but also maintained his stance that he is open to other negotiation models.
Doggett’s price-negotiation bill is the highest-profile proposal thus far with more than 100 House co-sponsors. It would allow HHS to negotiate prices for all Medicare Part D drugs, though Republicans largely inquired about how to address the costs of expensive, single-source drugs. — Rachel Cohrs (rcohrs@iwpnews.com)
Click here to see the original article on the Inside Health Policy website.
Recent Posts
-
SCPC Applauds Bipartisan Group of Lawmakers Calling for Critical Changes to Medicare Drug Price Negotiations
The Senior Care Pharmacy Coalition (SCPC), the leading national voice for the long-term care (LTC) pharmacy community, released the following statement commending Chairman Buddy Carter, Rep. Jake Auchincloss and other Members of Congress for urging HHS and CMS to examine the looming impact of Medicare drug price negotiations on America’s pharmacies.
-
SCPC Releases Statement in Support of Government Accountability Office (GAO) Report on the Inflation Reduction Act
SCPC has repeatedly warned about the impact of the Inflation Reduction Act’s (IRA) mandatory Medicare drug price negotiations on LTC pharmacies and the millions of vulnerable seniors they serve. We are glad the Government Accountability Office (GAO) is examining how these policies are affecting pharmacies, particularly LTC pharmacies, which already operate under a broken reimbursement model that often requires them to dispense many of the most commonly used medications at a loss.
-
SCPC Applauds President Trump’s Executive Order Calling on HHS and Congress to Improve the IRA, Rein In PBMs and Lower Drug Costs
The Senior Care Pharmacy Coalition (SCPC), the leading national voice for the long-term care (LTC) pharmacy community, released the following statement applauding President Trump’s recent Executive Order aimed at improving the Inflation Reduction Act (IRA), lowering drug prices and addressing the harmful actions of PBMs. “For far too long, pharmacy benefit managers (PBMs) have taken […]
Stay in the Know
Get the latest news and updates on issues impacting the long-term pharmacy community.